問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Radiation Therapy

Division of Radiology

Division of Cardiovascular Diseases

Kaohsiung Veterans General Hosptial (在職)

Division of Radiology

Division of Urology

更新時間：2023-09-19

王俊傑Wang, Chun-Chieh
  • Principal Investigator
  • Clinical Trial Experience (year) -24 years -4 個月

  • jjwang@cgmh.org.tw

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王俊傑

List

21Cases

2020-03-01 - 2025-03-31

Phase III

Not yet recruiting
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2017-11-01 - 2022-12-31

Phase I/II

Completed
A Phase 1b/2, Randomized, Double-Blind, PlaceboControlled, Multicenter, Parallel-Group Study of B-701 Plus Docetaxel Versus Placebo Plus Docetaxel in the Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma in Subjects who have Relapsed After, or are Refractory to Standard Therapy

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cell Carcinoma Urinary Bladder Disease Urological Diseases

  • Test Drug

    B-701

Participate Sites
9Sites

Terminated9Sites

2022-02-01 - 2029-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2026-08-01 - 2031-08-31

Phase II

Not yet recruiting
Cancer immunotherapy research targeting mismatch repair deficiency (dMMR): Multimodal integrated analysis combining hyperpolarized dynamic magnetic resonance (DNP) and artificial intelligence.

  • Condition/Disease

    Newly diagnosed or recurrent gynecological cancers confirmed by histology, including ovarian cancer, cervical cancer, endometrial cancer and other gynecological cancers.

  • Test Drug

    Hyperpolarized [1-13C]Pyruvate

Participate Sites
1Sites

Not yet recruiting1Sites

2015-12-01 - 2028-12-29

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated6Sites

馮思中
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2022-01-01 - 2031-02-27

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2021-03-31 - 2027-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting1Sites

Terminated15Sites

2021-03-01 - 2023-07-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2020-03-01 - 2027-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-12-20 - 2031-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB